Ironwood Pharmaceuticals (IRWD) vs Rigel Pharmaceuticals (RIGL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Ironwood Pharmaceuticals (IRWD) has outperformed Rigel Pharmaceuticals (RIGL) over the past year, gaining 48.7% versus a loss of 13.3%. Over five years, RIGL leads with a +44.7% price change compared with -57.9% for IRWD. Ironwood Pharmaceuticals is the larger company by market cap ($778.1 million vs $754.9 million), about 1.0 times the size, while Rigel Pharmaceuticals is growing revenue faster (+64.1% vs -15.7%).
On valuation, Ironwood Pharmaceuticals trades at a lower forward P/E (3.0x vs 8.4x for Rigel Pharmaceuticals). Rigel Pharmaceuticals converts more of its revenue into profit, with a net margin of 124.7% versus 8.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IRWD | RIGL |
|---|---|---|
| Share price | $4.70 | $40.09 |
| Market cap | $778.09M | $754.89M |
| 1-day change | -0.21% | -2.67% |
| YTD return | +39.47% | -6.40% |
| 1-year return | +48.73% | -13.26% |
| 5-year return | -57.89% | +44.73% |
| P/E ratio (TTM) | 5.22 | 2.49 |
| Forward P/E | 3.00 | 8.39 |
| EPS (TTM) | $0.90 | $16.07 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $296.15M | $294.28M |
| Revenue growth (YoY) | -15.72% | +64.15% |
| Net income (latest FY) | $24.02M | $367.02M |
| Gross margin | — | 93.33% |
| Operating margin | 33.26% | 42.63% |
| Net margin | 8.11% | 124.72% |
| 52-week high | $5.78 | $52.61 |
| 52-week low | $2.95 | $24.95 |
| Distance from 52-week high | -18.69% | -23.80% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +31.49% | +60.64% |
| Average volume | 2.15M | 248.06K |
| Shares outstanding | 165.55M | 18.83M |
| Employees | 100 | 172 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IRWD has outperformed RIGL by 62.0 percentage points over the past year.
- Ironwood Pharmaceuticals trades at a higher earnings multiple (5.2x vs 2.5x trailing P/E).
- Rigel Pharmaceuticals is more profitable, keeping 124.7 cents of every revenue dollar as net income versus 8.1 cents for Ironwood Pharmaceuticals.
- Rigel Pharmaceuticals grew revenue faster in its latest fiscal year (+64.15% vs -15.72%).
About Ironwood Pharmaceuticals
IRWD stock →Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
About Rigel Pharmaceuticals
RIGL stock →Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 172 employees
IRWD vs RIGL FAQ
Which is bigger, Ironwood Pharmaceuticals or Rigel Pharmaceuticals?
Ironwood Pharmaceuticals (IRWD) is larger, with a market capitalization of $778.09M compared with $754.89M for Rigel Pharmaceuticals (RIGL).
Which stock has performed better over the past year, IRWD or RIGL?
IRWD returned +48.73% over the past 12 months, compared with -13.26% for RIGL (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, IRWD or RIGL?
RIGL has the lower trailing P/E at 2.5, versus 5.2 for IRWD. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Ironwood Pharmaceuticals and Rigel Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.